AlzBiomarker

Dementia with Lewy Bodies vs Alzheimer's Disease: tau-p181 (CSF)

Tools

Back to the Top

Meta-analysis showed that levels of tau-p181 in the cerebrospinal fluid of people with dementia with Lewy bodies are about half those in people with Alzheimer's disease (effect size = 0.56, p <0.0001). For comparison, the level of tau-p181 in the CSF of control subjects is also about half that of people with AD. A meta-analysis comparing levels of phosphorylated tau—without specifying which phospho-epitopes—in people with DLB and control subjects reported that phospho-tau is elevated in the CSF of patients (van Harten et al., 2011).

Loading data...

How to interpret a forest plot: Each individual effect size (ES) is a ratio of the mean biomarker level in one condition over the mean level in another condition. An ES equal to 1 means that the two conditions had identical mean values. An ES > 1 indicates higher levels in the first condition, whereas an ES < 1 indicates lower levels in the first condition. The overall ES, indicated by a black diamond, is a weighted average of the individual effect sizes. The weight of each data point was determined by the inverse of the variance and is reflected in the size of each square. The width of the overall ES diamond is determined by the 95 percent confidence interval. Data out of range of the scale, including ES and confidence intervals, are indicated by an arrowhead at the edge of the plot, when applicable. 

Version 3.0, July 2021.